Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adma Biologics (NQ: ADMA )

1.940 -0.130 (-6.28%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 24, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 26,158,310
Open 2.080
Bid (Size) 1.960 (5)
Ask (Size) 2.010 (14)
Prev. Close 2.070
Today's Range 1.900 - 2.085
52wk Range 1.010 - 2.315
Shares Outstanding 196,351,925
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Looking Into ADMA Biologics's Return On Capital Employed
Benzinga Pro data, ADMA Biologics (NASDAQ:ADMA) reported Q1 sales of $29.10 million. Earnings fell to a loss of $25.01 million, resulting in a 50.2% decrease from last quarter. 
Via Benzinga
Recap: ADMA Biologics Q1 Earnings
ADMA Biologics (NASDAQ:ADMA) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings ADMA Biologics missed estimated... 
Via Benzinga

Performance

YTD
+31.97%
+31.97%
1 Month
N/A
N/A
3 Month
+10.23%
+10.23%
6 Month
+55.20%
+55.20%
1 Year
+12.79%
+12.79%

More News

Read More
Earnings Outlook For ADMA Biologics
Via Benzinga
The Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru's Pre-EUA Meeting, Conference Presentations And More
Via Benzinga
ADMA Biologics's Return On Capital Employed Overview
Via Benzinga
ADMA Biologics' Q4 Top-Line Surpass Estimates, Concludes $175M Debt Refinancing
Via Benzinga
Earnings Scheduled For March 24, 2022
Via Benzinga
ADMA Biologics's Earnings Outlook
Via Benzinga
The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout
Via Benzinga
ADMA Biologics Shares Gain As Interim Q4 Sales Beat Expectation
Via Benzinga
The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
91 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
54 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 11, 2021
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
ADMA Biologics Shares Rise On Lower Than Expected Q3 Loss, Sales Double
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
28 Stocks Moving in Thursday's Pre-Market Session
Via Benzinga
ADMA Biologics Inc (ADMA) Q3 2021 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
Via Benzinga
Exposures COVID-19
Preview: ADMA Biologics's Earnings
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2021
Via Benzinga
3 Penny Stocks Insiders Are Buying
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.